The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

The PFA-SHAM trial and MANIFEST-US registry support the efficacy and safety of the increasingly used ablation modality.

EchoPrime was trained on more than 12 million videos; it’s now being tested clinically, with more data expected next year.

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers ...

The answer is very clear that if you have MI and preserved EF, there is no benefit of using a beta-blocker. Sripal Bangalore ...

In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

NEW ORLEANS, LA—Complete revascularization in patients presenting with ACS and multivessel coronary artery disease ...

Quantifying blood flow instead of relying on angiography alone led to a change in diagnosis for 53% of patients.